Correlation Between Okta and Spero Therapeutics
Can any of the company-specific risk be diversified away by investing in both Okta and Spero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Okta and Spero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Okta Inc and Spero Therapeutics, you can compare the effects of market volatilities on Okta and Spero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Okta with a short position of Spero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Okta and Spero Therapeutics.
Diversification Opportunities for Okta and Spero Therapeutics
0.33 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Okta and Spero is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Okta Inc and Spero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spero Therapeutics and Okta is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Okta Inc are associated (or correlated) with Spero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spero Therapeutics has no effect on the direction of Okta i.e., Okta and Spero Therapeutics go up and down completely randomly.
Pair Corralation between Okta and Spero Therapeutics
Given the investment horizon of 90 days Okta Inc is expected to generate 0.54 times more return on investment than Spero Therapeutics. However, Okta Inc is 1.85 times less risky than Spero Therapeutics. It trades about 0.13 of its potential returns per unit of risk. Spero Therapeutics is currently generating about -0.14 per unit of risk. If you would invest 7,325 in Okta Inc on August 27, 2024 and sell it today you would earn a total of 332.00 from holding Okta Inc or generate 4.53% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Okta Inc vs. Spero Therapeutics
Performance |
| Timeline |
| Okta Inc |
| Spero Therapeutics |
Okta and Spero Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Okta and Spero Therapeutics
The main advantage of trading using opposite Okta and Spero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Okta position performs unexpectedly, Spero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will offset losses from the drop in Spero Therapeutics' long position.The idea behind Okta Inc and Spero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Spero Therapeutics vs. Assembly Biosciences | Spero Therapeutics vs. Achilles Therapeutics PLC | Spero Therapeutics vs. Instil Bio | Spero Therapeutics vs. CytomX Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Complementary Tools
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |